Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages

  Fujita, Koji ^a   Roforth, Matthew M ^a   Demaray, Susan ^a   McGregor, Ulrike ^a   Kirmani, Salman ^a   McCready, Louise K ^a   Peterson, James M ^a   Drake, Matthew T ^a   Monroe, David G ^a   Khosla, Sundeep ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SCLEROSTIN; SCLEROSTIN DOMAIN CONTAINING PROTEIN 1; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE LEVEL; BONE METABOLISM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FRACTURE; GENETIC ASSOCIATION; GENETIC REGULATION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HUMAN TISSUE; NEEDLE BIOPSY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; ESTROGENS; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HUMANS; NF-KAPPA B; POSTMENOPAUSE; PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84892174592     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3249     Document Type: Article

References (48)

1. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
2. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279-302.
3. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. J Clin Invest. 1998;101:1942-1950.
4. Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL. Effect of blockade of TNFα and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res. 2007;22:724-729.
5. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13:1124-1133.
6. Modder UIL, Clowes JA, Hoey K, et al. Regulation of circulating sclerostin levels by sex steroids in women and men. J Bone Miner Res. 2011;26:27-34.
7. Lean JM, Chow JW, Chambers TJ. The rate of cancellous bone formation falls immediately after ovariectomy in the rat. J Endocrinol. 1994;142:119-125.
8. Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007; 148:2635-2643.
9. Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202-1209.
10. Armstrong VJ, Muzylak M, Sunters A, et al. WNT/B-catenin signaling is a component of osteoblastic bone cells' early responses to load-bearing, and requires estrogen receptor α. J Biol Chem. 2007; 282:20715-20727.
11. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589.
12. Balemans W, Ebeling M, Patel N, et al. Increase bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-543.
13. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:144-152.
14. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91-97.
15. Li X, Ominsky MS, Niu Q-T, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-869.
16. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24:578-588.
17. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95:1991-1997.
18. Modder UI, Roforth MM, Hoey K, et al. Effects of estrogen on osteoprogenitor cells and cytokines/bone regulatory factors in postmenopausal women. Bone. 2011;49:202-207.
19. Chung YE, Lee SH, Lee S-Y, et al. Long-term treatment with raloxifene, but not bisphosphonates reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int. 2012;23:1235-1243.
20. Kim B-J, Bae SJ, Lee S-Y, et al. TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition. Biochem Biophys Res Comm. 2012;424:170-175.
21. Jastrzebski S, Kalinowski J, Stolina M, et al. Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res. 2013;28:618-626.
22. Lintern KB, Guidato S, Rowe A, Saldanha JW, Itasaki N. Characterization of wise protein and its molecular mechanism to interact with Wnt and BMP signals. J Biol Chem. 2009;284:23159-23168.
23. He JW, Yue H, Hu HH, Hu YQ, Zhang ZL. Contribution of the sclerostin domain-containing protein 1 (SOSTDC1) gene to normal variation of peak bone mineral density in Chinese women and men. J Bone Miner Res. 2011;29:571-581.
24. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide metaanalysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44:491-501.
25. Wei W, Zeve D, Suh JM, et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by α-catenin. Mol Cell Biol. 2011;31:4706-4719.
26. Modder UI, Roforth MM, Nicks KM, et al. Characterization of mesenchymal progenitor cells isolated from human bone marrow by negative selection. Bone. 2012;50:804-810.
27. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004;313:856-862.
28. Vandesompele J, DePreter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3: research0034.0031-0030-0034.0011.
29. Zhao S, Fernald RD. Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol. 2005;12:1047-1064.
30. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079-1087.
31. Syed FA, Modder UI, Roforth M, et al. Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J Bone Miner Res. 2010;25:2438-2446.
32. Peris P, Atkinson EJ, Gossl M, et al. Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women. Mayo Clin Proc. 2013;88:46-55.
33. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003;19:368-375.
34. Hirakawa A, Sato Y, Sozu T, Hamada C, Yoshimura I. Estimating the false discovery rate using mixed normal distribution for identi fying differentially expressed genes in microarray data analysis. Cancer Inform. 2008;22:140-148.
35. Kusu N, Laurikkala J, Imanishi M, et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol chem. 2003;278:24113-24117.
36. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA. 2009;105:20764-20769.
37. Ota K, Quint P, Ruan M, et al. Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem. 2013;114:1901-1907.
38. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLos ONE. 2011;6: e19595.
39. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33:747-783.
40. Murashima-Suginami A, Takahashi K, Kawabata T, et al. Rudiment incisors survive and erupt as supernumerary teeth as a result of USAG-1 abrogation. Biochem Biophys ResComm. 2007;359:549-555.
41. Murashima-Suginami A, Takahashi K, Sakata T, et al. Enhanced BMP signaling results in supernumerary tooth formation in USAG-1 deficient mouse. Biochem Biophys Res Comm. 2008;369:1012-1016.
42. Chang J, Wang Z, Tang E, et al. Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat Med. 2009;15:682-689.
43. Hilton MJ, Tu X, Wu X, et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med. 2008;14:306-314.
44. Canalis E, Parker K, Feng JQ, Zanotti S. Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology. 2013; 154:623-634.
45. Ichikawa S, Baujat G, Seyahi A, et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A. 2010;152A:896-903.
46. Carillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, Fernandez- Martin JL, Naves-Diaz M, Cannata-Andia JB. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 2009;20:2009-2017.
47. Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopotrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522-536.
48. Fujita K, Roforth M, Atkinson EJ, et al. Isolation and characterization of human osteoblasts from needle biopsies without in vitro culture [published online October 11, 2013]. Osteoporos Int. doi: 10.1007/s00198-013-2529-9.